Editas MedicineEDIT
About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Employees: 226
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
97% more call options, than puts
Call options by funds: $668K | Put options by funds: $339K
5% less funds holding
Funds holding: 203 [Q4 2024] → 193 (-10) [Q1 2025]
8.79% less ownership
Funds ownership: 61.83% [Q4 2024] → 53.03% (-8.79%) [Q1 2025]
21% less capital invested
Capital invested by funds: $64.8M [Q4 2024] → $51M (-$13.8M) [Q1 2025]
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
25% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 59
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Baird Joel Beatty | 103%upside $4 | Outperform Maintained | 13 May 2025 |
HC Wainwright & Co. Mitchell Kapoor | 52%upside $3 | Buy Initiated | 28 Apr 2025 |
Financial journalist opinion
Based on 4 articles about EDIT published over the past 30 days
